ClinicalTrials.gg
CompletedNCT00831597904Updated Apr 19, 2016

Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

A Phase 2 interventional study of bendamustine and rituximab in Diffuse Large B-Cell Lymphoma, sponsored by Pharmatech. Completed at 33 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-04-19.

Sponsored by Pharmatech · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
61
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 21 studies testing bendamustine in Lymphoma, Large B-Cell, Diffuse — 3 open to participants now, 5 under way, 1 of them phase 3. bendamustine · Lymphoma, Large B-Cell, Diffuse.

Enrollment
4th of 21
61 · median 37
Started
2008
with 1 other
Phase 2
11 of 21
1 open now
Registered
2nd of 21
by date
Lead sponsor
1 of 21
Pharmatech

Among the 21 studies testing bendamustine in Lymphoma, Large B-Cell, Diffuse, this one is the 4th largest by enrollment, is one of 2 that started in 2008, is one of 11 in phase 2, and was the 2nd registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

3 of the 21 studies testing bendamustine in Lymphoma, Large B-Cell, Diffuse are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About bendamustine

bendamustine: first FDA approval 2008 (TREANDA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing bendamustine in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

A phase II trial to evaluate the efficacy and safety of combination bendamustine and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. It is hypothesized that the BR combination will produce at least a 70% overall response rate.

03

Conditions studied

  • Diffuse Large B-Cell Lymphoma

Keywords

  • Lymphoma
  • B-Cell
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed CD20-positive, diffuse large B-cell lymphoma
  • with at least one bidimensional lymph node or tumor mass > 1.5 cm in the longest diameter that can be followed for response as a target lesion as measured by PET or CT
  • after at least one prior therapeutic treatment for diffuse large B-cell lymphoma. Relapsed is defined as patients who initially responded and then progressed. Refractory is defined as patients, whom in the judgment of the Investigator, received adequate prior treatment and did not respond during treatment or progressed within 60 days of last treatment. Relapse following an stem cell transplant allowed.
  • (ECOG) Performance Status (PS) 0-2
  • Patient must understand and voluntarily sign IRB-approved
  • ≥ three (3) months
  • Age ≥ 18 years old
  • Laboratory parameters:

    • ≥ 1,000 cells/mm(3)
    • count ≥ 75,000 cells/mm(3)
    • ≥ 8 g/dL
    • Creatinine ≤ 2.0 mg/dL or ≥ 50 mL/min (calculated or 24-hr urine sample)
    • /SGOT 2.0 x (≤ 5.0 x ULN if secondary to liver )
    • ALT/SGPT 2.0 x ULN (≤ 5.0 x ULN if secondary to liver metastases)
    • Total ≤ 2.0 x ULN

Exclusion criteria

Exclusion Criteria:

  • Patients with active/symptomatic central nervous system (CNS) involvement based on clinical evaluation. Previously treated CNS involvement that has remained asymptomatic for ≥ 90 days allowed if no CNS involvement shown by lumbar puncture, PET, CT or MRI.
  • Prior treatment with bendamustine
  • Known sensitivity to bendamustine or any component of bendamustine
  • Known anaphylaxis or immunoglobulin E (IgE) mediated to murine proteins or sensitivity to rituximab or any component of rituximab
  • Eligible for stem cell transplant (patients who refuse procedure will not be excluded)
  • Prior stem cell transplant within 6 months of Cycle 1, Day 1
  • Major surgery, not related to debulking procedures, within 21 days of Cycle 1, Day 1. Patients undergoing debulking procedures and minor surgery are allowed after a recovery period, in the judgment of the Investigator.
  • Chemotherapy, immunotherapy, or irradiation within 28 days of Cycle 1, Day 1 (within 6 weeks for nitrosoureas or mitomycin). Patients on high dose must have tapered to a stable dose equivalent to Prednisone ≤ 15 mg per day within 28 days of Cycle 1, Day 1.
  • Prior radioimmunotherapy (i.e. Zevalin®) within 10 weeks of Cycle 1, Day 1
  • Prior use of anti-cancer agents within 28 days of Cycle 1, Day 1
  • Unresolved toxicities ≥ grade 2 from previous therapy
  • Pregnant or lactating females. Females of (FCBP) and non-vasectomized men must agree to use effective methods of during and 28 days following treatment period. FCBP must have a negative pregnancy test.
  • -related lymphoma
  • Known active HIV or infection, or known seropositivity for HIV, or current or chronic or HCV infection. HBV test required at screening or within 6 months of screening and must indicate negative result. Patients with seropositivity presumed to be due to prior vaccination against Hepatitis B or resolved infection are not excluded (see HBV reactivation guidelines included in rituximab prescribing information).
  • Concurrent active or history of other , except nonmelanoma skin cancer or carcinoma in situ of cervix or breast. Patients with previous malignancies are eligible provided they have been disease free for ≥ 1 year.
  • Serious (grade 3-4), active, intercurrent infection requiring therapy, or deep seated or systemic mycotic infections
  • Myocardial infarction within 6 months prior to registration or New York Hospital Association () Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or significant conduction system abnormalities, in the judgment of the Investigator
  • Thyroid disease in which thyroid function cannot be maintained within normal range, in the judgment of the Investigator
  • Concurrent uncontrolled serious medical or psychiatric conditions likely to interfere with participation in this clinical study, in the judgment of the Investigator
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    Bendamustine with rituximab

    All patients received combination bendamustine with rituximab

    Drug: bendamustine · Drug: rituximab

Interventions

  • 120 mg/m2 IV, Days 1, 2 of Cycles 1-6

    Also known as: Treanda

  • 375 mg/m2 IV, Day 1 of Cycles 1-6

    Also known as: Rituxan

06

What researchers measure

Primary outcomes

  1. Best Overall Response Rate (ORR) of bendamustine in combination with rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma

    Time frame: 1 year for 1st assessment and then 2.5 years for final assessment

Secondary outcomes

  1. Duration of Response (DOR)

    Time frame: 1 year for 1st assessment and then 2.5 years for final assessment

  2. Time to Progression (TTP)

    Time frame: 1 year for 1st assessment and then 2.5 years for final assessment

  3. Progression-Free Survival (PFS)

    Time frame: 1 year for 1st assessment and then 2.5 years for final assessment

  4. Safety Profile of Study Treatment

    Time frame: 1 year for 1st assessment and then 2.5 years for final assessment

  5. Overall Survival (OS)

    Time frame: 1 year for 1st assessment and then 2.5 years for final assessment

07

Study locations

33 sites
  • Pharmatech Oncology Study Site
    Beverly Hills, California 90211, United States
  • Pharmatech Oncology Study Site
    Fountain Valley, California 92708, United States
  • Pharmatech Oncology Study Site
    Oxnard, California 93030, United States
  • Pharmatech Oncology Study Site
    Washington, District of Columbia 20037, United States
  • Pharmatech Oncology Study Site
    Washington, District of Columbia 20422, United States
  • Pharmatech Oncology Study Site
    Boynton Beach, Florida 33435, United States
  • Pharmatech Oncology Study Site
    Brooksville, Florida 34613, United States
  • Pharmatech Oncology Study Site
    Gainesville, Florida 32605, United States
  • Pharmatech Oncology Study Site
    Titusville, Florida 32796, United States
  • Pharmatech Oncology Study Site
    Joliet, Illinois 60435, United States
  • Pharmatech Oncology Study Site
    Lafayette, Indiana 47904, United States
  • Pharmatech Oncology Study Site
    Muncie, Indiana 47303, United States
  • Pharmatech Oncology Study Site
    Dubuque, Iowa 52001, United States
  • Pharmatech Oncology Study Site
    Paducah, Kentucky 42001, United States
  • Pharmatech Oncology Study Site
    York, Maine 03909, United States
  • Pharmatech Oncology Study Site
    Jackson, Mississippi 39202, United States
  • Pharmatech Oncology Study Site
    Chesterfield, Missouri 63017, United States
  • Pharmatech Oncology Study Site
    Cherry Hill, New Jersey 08003, United States
  • Pharmatech Oncology Study Site
    Phillipsburg, New Jersey 08865, United States
  • Pharmatech Oncology Study Site
    Bay Shore, New York 11706, United States
  • Pharmatech Oncology Study Site
    Bronx, New York 10467, United States
  • Pharmatech Oncology Study Site
    East Setauket, New York 11733, United States
  • Pharmatech Oncology Study Site
    Akron, Ohio 44304, United States
  • Pharmatech Oncology Study Site
    Columbus, Ohio 43219, United States
  • Pharmatech Oncology Study Site
    Bethlehem, Pennsylvania 18015, United States
  • Pharmatech Oncology Study Site
    Gettysburg, Pennsylvania 17325, United States
  • Pharmatech Oncology Study Site
    Hilton Head, South Carolina 29926, United States
  • Pharmatech Oncology Study Site
    Germantown, Tennessee 38138, United States
  • Pharmatech Oncology Study Site
    Austin, Texas 78759, United States
  • Pharmatech Oncology Study Site
    Corpus Christi, Texas 78463, United States
  • Pharmatech Oncology Study Site
    Fort Worth, Texas 76104, United States
  • Pharmatech Oncology Study Site
    Lubbock, Texas 79410, United States
  • Pharmatech Oncology Study Site
    Richardson, Texas 75080, United States
08

References and documents

Publications

  • Vacirca JL, Acs PI, Tabbara IA, Rosen PJ, Lee P, Lynam E. Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma. Ann Hematol. 2014 Mar;93(3):403-9. doi: 10.1007/s00277-013-1879-x. Epub 2013 Aug 17. PubMed 23955074 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2008, a primary completion of Aug 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2009
First posted
Jan 29, 2009
Start
Nov 2008
Primary completionActual
Aug 2013
CompletionActual
Sep 2013
Last update
Apr 19, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 19, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00831597
Lead sponsor
Pharmatech
Collaborators
Cephalon
Responsible party
Sponsor
First posted
Jan 29, 2009
Start date
Nov 2008
Primary completion
Aug 2013
Completion
Sep 2013
Last update
Apr 19, 2016

Study contacts

Jeffrey L Vacirca, MD, FACP
principal investigator · University Hospital, Stony Brook North Shore Hematology/Oncology Associates

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bendamustine · Rituximab

Start the discussion